Lingkun Kong1, Amit R Bhatt1, Ann B Demny2, David K Coats1, Alexa Li3, Effie Z Rahman3, O'Brian E Smith4, Paul G Steinkuller1. 1. Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, United States. 2. Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States. 3. School of Medicine, Baylor College of Medicine, Houston, Texas, United States. 4. Department of Pediatrics and Biostatistics, Baylor College of Medicine, Houston, Texas, United States.
Abstract
PURPOSE: To measure serum levels of bevacizumab and to compare serum levels of free vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants who were treated with either intravitreal injection ofbevacizumab (IVB) or laserfor type 1 retinopathy of prematurity (ROP). METHODS:Twenty-four infants with type 1 ROP were randomized into three treatment groups: IVB at 0.625 mg per eye per dose, IVB at 0.25 mg per eye per dose, and laser. Blood samples were collected prior to treatment and on posttreatment days 2, 14, 42, and 60. Weekly body weights were documented from birth until 60 days post treatment. Serum levels of bevacizumab, free VEGF, and IGF-1 were measured with enzyme-linked immunosorbent assay (ELISA). RESULTS:Serum bevacizumab was detected 2 days after the injection, peaked at 14 days, and persisted for up to 60 days with half-life of 21 days. Area under the curve (AUC) analysis showed that systemic exposure to bevacizumab was variable among the subjects and was dose dependent. Serum free VEGF levels decreased in all three subgroups 2 days post treatment, with more significant reductions found in both IVB-treated groups, P = 0.0001. Serum IGF-1 levels were lower in both IVB-treated groups. CONCLUSIONS: Clearance of bevacizumab from the bloodstream in premature infants takes at least 2 months. Although serum free VEGF levels decreased following either laser or bevacizumab treatment, the reductions were more significant in the IVB-treated groups. Potential long-term effects of systemic exposure to bevacizumab in infants need to be studied further. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
RCT Entities:
PURPOSE: To measure serum levels of bevacizumab and to compare serum levels of free vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants who were treated with either intravitreal injection of bevacizumab (IVB) or laser for type 1 retinopathy of prematurity (ROP). METHODS: Twenty-four infants with type 1 ROP were randomized into three treatment groups: IVB at 0.625 mg per eye per dose, IVB at 0.25 mg per eye per dose, and laser. Blood samples were collected prior to treatment and on posttreatment days 2, 14, 42, and 60. Weekly body weights were documented from birth until 60 days post treatment. Serum levels of bevacizumab, free VEGF, and IGF-1 were measured with enzyme-linked immunosorbent assay (ELISA). RESULTS: Serum bevacizumab was detected 2 days after the injection, peaked at 14 days, and persisted for up to 60 days with half-life of 21 days. Area under the curve (AUC) analysis showed that systemic exposure to bevacizumab was variable among the subjects and was dose dependent. Serum free VEGF levels decreased in all three subgroups 2 days post treatment, with more significant reductions found in both IVB-treated groups, P = 0.0001. Serum IGF-1 levels were lower in both IVB-treated groups. CONCLUSIONS: Clearance of bevacizumab from the bloodstream in premature infants takes at least 2 months. Although serum free VEGF levels decreased following either laser or bevacizumab treatment, the reductions were more significant in the IVB-treated groups. Potential long-term effects of systemic exposure to bevacizumab in infants need to be studied further. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
Entities:
Keywords:
VEGF; bevacizumab; intraocular injection; laser; retinopathy of prematurity
Authors: David K Wallace; Trevano W Dean; Mary Elizabeth Hartnett; Lingkun Kong; Lois E Smith; G Baker Hubbard; Mary Lou McGregor; Catherine O Jordan; Iason S Mantagos; Edward F Bell; Raymond T Kraker Journal: Ophthalmology Date: 2018-06-07 Impact factor: 12.079
Authors: Andreas Stahl; Tim U Krohne; Nicole Eter; Isabel Oberacher-Velten; Rainer Guthoff; Synke Meltendorf; Oliver Ehrt; Sabine Aisenbrey; Johann Roider; Heinrich Gerding; Claudia Jandeck; Lois E H Smith; Johanna M Walz Journal: JAMA Pediatr Date: 2018-03-01 Impact factor: 16.193
Authors: Nader Sheibani; Ismail S Zaitoun; Shoujian Wang; Soesiawati R Darjatmoko; Andrew Suscha; Yong-Seok Song; Christine M Sorenson; Victor Shifrin; Daniel M Albert; Ignacio Melgar-Asensio; Irawati Kandela; Jack Henkin Journal: Exp Eye Res Date: 2020-04-06 Impact factor: 3.467
Authors: Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Pediatr Res Date: 2016-11-14 Impact factor: 3.756
Authors: Lee M Jampol; Adam R Glassman; Danni Liu; Lloyd Paul Aiello; Neil M Bressler; Elia J Duh; Susan Quaggin; John A Wells; Charles C Wykoff Journal: Ophthalmology Date: 2018-03-07 Impact factor: 12.079